Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02660346 · ClinicalTrials.gov registry record · Phase 4
IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB
A Phase 4 study, sponsored by Sharp HealthCare.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT02660346: Completed Phase 4 study, sponsored by Sharp HealthCare.
NCT02660346 is a Phase 4 study that has completed, run by Sharp HealthCare. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02660346, a Phase 4 study, has completed, sponsored by Sharp HealthCare.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
Patients with MRSaB have high therapeutic failure rates and mortality rates. Recent studies have shown that an elevated IL-10 level is an independent risk factor of mortality. It may also serve as biomarker for very early risk stratification. The aim of this study is to compare the outcomes for patients with elevated IL-10 levels (≥8 pg/ml) when treated with standard antibiotic therapy (daptomycin or vancomycin) versus early aggressive therapy (daptomycin with ceftaroline) for the treatment of MRSaB.
Interventions
- DRUG Vancomycin
- DRUG Ceftaroline
- DRUG Daptomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-11 |
| Est. Completion | 2018-01-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02660346
The ClinicalTrials.gov registry entry for NCT02660346 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sharp HealthCare, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vancomycin is the first listed.
NCT02660346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02660346 about?
NCT02660346 is a clinical study titled "IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB". Patients with MRSaB have high therapeutic failure rates and mortality rates. Recent studies have shown that an elevated IL-10 level is an independent risk factor of mortality. It may also serve as biomarker for very early risk stratification. The aim of this study is to compare the outcomes for pati...
What is the current status of trial NCT02660346?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2015-11. Estimated completion is 2018-01-30.
What interventions are being tested in trial NCT02660346?
The interventions under investigation include: Vancomycin (DRUG), Ceftaroline (DRUG), Daptomycin (DRUG).
Who is sponsoring clinical trial NCT02660346?
This trial is sponsored by Sharp HealthCare, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.